plerixafor has been researched along with B-Cell Chronic Lymphocytic Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andritsos, LA; Burger, JA; Byrd, JC; Cheverton, P; Kipps, TJ; Sivina, M; Wu, J | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Buggins, AG; Devereux, S; Fegan, C; Forconi, F; Jones, CH; Pepper, C; Pratt, G; Stevenson, FK; Walsby, EJ | 1 |
| Ale-Ali, A; Amaya-Chanaga, CI; Cardarelli, PM; Castro, JE; Choi, MY; Cohen, LJ; Jones, H; Kashyap, MK; Kipps, TJ; Kuhne, MR; Kumar, D; Melo-Cardenas, J; Rassenti, LZ; Sabbatini, P; Shelat, SG | 1 |
| Bron, D; Cymbalista, F; De Bruyn, C; Lagneaux, L; Le Roy, C; Meuleman, N; Mineur, P; Pieters, K; Saint-Georges, S; Stamatopoulos, B; Varin-Blank, N | 1 |
1 review(s) available for plerixafor and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
1 trial(s) available for plerixafor and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Follow-Up Studies; Heterocyclic Compounds; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Rituximab; Survival Rate; Tissue Distribution; Young Adult | 2019 |
3 other study(ies) available for plerixafor and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Class I Phosphatidylinositol 3-Kinases; Cyclams; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Heterocyclic Compounds; Humans; Immunoglobulin Heavy Chains; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Natalizumab; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Signal Transduction; Survival Analysis | 2015 |
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Topics: Actins; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Enzyme Activation; Heterocyclic Compounds; Humans; Imino Furanoses; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Pyrimidinones; Reactive Oxygen Species; Receptors, CXCR4; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Topics: Actins; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Communication; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Heterocyclic Compounds; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Mesenchymal Stem Cells; Protein Binding; Protein Multimerization; Receptors, CXCR4; Tumor Microenvironment | 2012 |